The diagnostic value of systemic immune-inflammation index in diabetic macular oedema

Basit Öğe Kaydı
dc.authoridozcan, sait coskun/0000-0002-0608-9371
dc.authoridOzarslan Ozcan, Deniz/0000-0003-2814-1975
dc.contributor.authorElbeyli, Ahmet
dc.contributor.authorKurtul, Bengi Ece
dc.contributor.authorOzcan, Sait Coskun
dc.contributor.authorOzcan, Deniz Ozarslan
dc.date.accessioned2024-09-18T20:15:10Z
dc.date.available2024-09-18T20:15:10Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground This study evaluates the diagnostic value of systemic immune-inflammation index (SII) in the occurrence of DME in patients with non-proliferative diabetic retinopathy. Methods In this prospective study, the SII was applied to 150 consecutive patients with non-proliferative diabetic retinopathy. The relationship between the SII and the occurrence of DME was examined. Patients with DME were also divided into two subgroups according to the presence of accompanying sub-retinal fluid. The SII value was calculated as follows: platelet count x (neutrophil/lymphocyte). The risk factors for DME were evaluated using multivariate logistic regression analysis. A receiver operating characteristic (ROC) curve analysis of SII for predicting DME was performed. Results Patients with DME had significantly higher levels of SII than those without DME (599.7 +/- 279.2 and 464. 9 +/- 172.2, respectively, p < 0.001). However, The SII values were similar between sub-retinal fluid subgroups. Multivariate regression analysis indicated that SII, together with duration of diabetes, was an independent factor for DME occurrence [Odds ratio (OR) = 1.005, 95% confidence interval = 1.001-1.009, p = 0.04, and OR = 1.146, 95% CI = 1.049-1.252, p = 0.003, respectively]. ROC curve analysis revealed that the best cut-off value of SII was 399 (area under the curve: 0.633; sensitivity: 70%; specificity: 60%). Conclusion An elevated SII value is strongly associated with the development of DME. The SII may be a diagnostic biomarker for identifying DME to improve the risk stratification and management of non-proliferative patients with diabetic retinopathy.en_US
dc.identifier.doi10.1080/08164622.2021.1994337
dc.identifier.endpage835en_US
dc.identifier.issn0816-4622
dc.identifier.issn1444-0938
dc.identifier.issue8en_US
dc.identifier.pmid34763621en_US
dc.identifier.scopus2-s2.0-85119188769en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage831en_US
dc.identifier.urihttps://doi.org/10.1080/08164622.2021.1994337
dc.identifier.urihttps://hdl.handle.net/20.500.12483/9488
dc.identifier.volume105en_US
dc.identifier.wosWOS:000717391400001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofClinical and Experimental Optometryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetic macular oedemaen_US
dc.subjectdiabetic retinopathyen_US
dc.subjectsubretinal fluiden_US
dc.subjectsystemic immune-inflammation indexen_US
dc.titleThe diagnostic value of systemic immune-inflammation index in diabetic macular oedemaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu